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Background:  Left Ventricular Assist Devices (LVADs) provide long-term bridge support to transplantation limited by implantation risk, 
thromboembolism, bleeding, infections, immune-activation and cost. Non-LVAD circulatory assist devices (TandemHeart, ECMO, femoral IAPBs) 
are limited by their short durations of circulatory support. We report our experience to date using ambulatory axillary IABPs (ABP) for successful 
intermediate term bridge support to long-term LVAD implant or transplant.
Methods:  We reviewed patients listed for heart transplant January 1, 2003, through September 1, 2010, who underwent mechanical assist device 
support of any kind, including ABP. Information included device selection criteria, implantation outcomes, longer term outcomes, duration of support, 
functional status, complications, length of stay and cost.
Results:  Sixteen patients to date underwent ABP placement. Prior to ABP placement, all patients had NYHA class IV heart failure on maximal 
medical therapy including IV inotropes. All patients had a relative contraindication to LVAD implantation and underwent successful placement of 
an ABP through the left axillary artery without complication. All patients ambulated within one week following ABP implant. ABP support ranged from 
4 to 59 days. Thirteen patients had successful transplant and hospital discharge. Of the remaining three patients, one successfully transitioned to 
long term VAD after several weeks of APB support, one died in hospital of multi-system organ failure on the APB while awaiting transplant, one died 
18 days after removal of an ABP that provided stable support for 59 days. No infections, thromboembolism, bleeding or immune-activation occurred 
due to an ABP. Compared to patients supported with conventional LVADs, ABP patients experienced improved rehabilitation, fewer complications and 
lower cost.
Conclusions:  In our initial experience in 16 patients, ABP provided safe, effective and well-tolerated intermediate term bridging to long-term LVAD 
implantation or transplantation. Compared to conventional LVADs, ABPs are associated with functional improvement, improved patient satisfaction, 
fewer complications and lower cost.
